Abstract
SINCE DODDS (1, 2) first reported the estrogenic effects of stilbestrol there have been numerous reports of clinical trials with this interesting drug. Bishop (3) reported that in 17 of 25 women it controlled the symptoms of the menopause. He ad-ministered stilbestrol to a total of 46 patients of all types, only 3 of whom developed nausea and vomiting. A breast biopsy, made on one patient after she had received 280 mg. of stilbestrol, showed increased epithelial activity but no evidence of carcinoma. Winterton and MacGregor (4) observed nausea in 6 of 51 patients treated for amenorrhea, dysmenorrhea or the menopause. In 5 this symptom was slight and in one, severe enough to require omission of the drug. No other toxic reactions were noted. Others have reported similar results (5-14). Moricard and Saulnier (15), on the other hand, reported nausea in 7 of 12 patients. In 3 it was severe enough to make omission of the drug necessary. General malaise, nausea, vomiting and dizziness occurred in a large percent...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Journal of Clinical Endocrinology & Metabolism
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
